Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Letrozole + Pelareorep |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Letrozole | Femara | Letrozol | Aromatase Inhibitor 3 | Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
Pelareorep | REOLYSIN | RAS Inhibitor (Pan) 11 | Reolysin (Pelareorep) is a reovirus, which specifically infects and replicates in RAS-activated cells to induce apoptosis, and may also induce anti-tumor immune response (PMID: 29799479). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04102618 | Phase I | Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trastuzumab Letrozole + Pelareorep Atezolizumab + Letrozole + Pelareorep | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1) | Terminated | ESP | 0 |